Chinook Therapeutics Inc - ESG Rating & Company Profile powered by AI
Other corporations in the rating peer group for Chinook Therapeutics Inc are shown below. This ESG rating for Chinook Therapeutics Inc represents the company's transparency towards the UN SDGs. This webpage displays a zero-cost E,S&G analysis covering Chinook Therapeutics Inc.
Chinook Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.7; made up of an environmental score of 6.0, social score of 6.4 and governance score of 1.6.
4.7
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 816 | Pliant Therapeutics Inc | 4.8 | High |
| 816 | Voyager Therapeutics Inc | 4.8 | High |
| 837 | Chinook Therapeutics Inc | 4.7 | High |
| 837 | Bio Rad Laboratories Inc | 4.7 | High |
| 837 | Katakura Industries Co Ltd | 4.7 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Chinook Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Chinook Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Chinook Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Chinook Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Chinook Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Chinook Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Chinook Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Chinook Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Chinook Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Chinook Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Chinook Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Chinook Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Chinook Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Chinook Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Chinook Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Chinook Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Chinook Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Chinook Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Chinook Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Chinook Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Chinook Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Chinook Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Chinook Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Chinook Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Chinook Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Chinook Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Chinook Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Chinook Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Chinook Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Chinook Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Chinook Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Chinook Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Chinook Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Chinook Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Chinook Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Chinook Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Chinook Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.